How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment

A couple years back, some cardiovascular specialists at Boston’s Brigham and Women’s Hospital stumbled across a surprising result. Novartis had tasked them with carrying out the long-range Phase III trial for canakinumab, an experimental anti-inflammatory drug the company was trying to market for cardiovascular disease. The main results were mixed — modest reductions in fatal … Continued

Read More